63 
Altasciences' comprehensive, integrated solution for clinical supply manufacture
Bio Pharma Dive
DECEMBER 7, 2020
Integrated CRO/CDMO solutions for accelerated and more efficient early drug development programs
Clinical Supply Related Topics 
A Novel Approach to Clinical Supply Chain Systems Integration
Journal for Clinical Studies
JUNE 14, 2021
In an era of rapid transformation in clinical trials, research sponsors are presented with new logistical and clinical supply management… The post A Novel Approach to Clinical Supply Chain Systems Integration appeared first on Journal for Clinical Studies.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Signant clinical supply chain software offers end-to-end visibility
Outsourcing Pharma
SEPTEMBER 22, 2021
SmartSignals Supplies is designed to help trial teams get a handle on clinical trial supply chain management to avoid delays, waste, and cost overruns.
Vitruvia Medical’s first Circular Clinic Supply Center for robotic instruments goes live with first customers
BioTech 365
JULY 1, 2021
Vitruvia Medical’s first Circular Clinic Supply Center for robotic instruments goes live with first customers Schönebeck, July … Continue reading → EQS NewsfeedDGAP-News: Vitruvia Medical AG / Key word(s): Corporate Action/Agreement 01.07.2021 / 10:33 The issuer is solely responsible for the content of this announcement.
[Webinar] How biotech companies can improve clinical supply planning and distrib…
The Pharma Data
SEPTEMBER 15, 2020
Find out solutions to mitigate the impact from clinical supply chain risk and discover how to improve dynamic drug supply forecasting strategies. Enrolling study subjects, setting up patient randomization and managing drug supply are critical to the success of a clinical trial.
PCI Pharma Services Announces Global Expansion of Clinical Trial Services
Journal for Clinical Studies
JULY 30, 2020
PCI Broadens Global Clinical Supply-Chain Service Offerings Into Mainland Europe PHILADELPHIA – July 28, 2020 – PCI Pharma Services (PCI),… Europe Regional News
Catalent looks to meet needs of expanding CGT market, completes expansion work at biologics drug substance facility
BioPharma Reporter
APRIL 27, 2021
Contract development and manufacturing organization, Catalent, has invested in the capabilities at its clinical supply services facility in Philadelphia, in the US, to further support biotech firms developing cell and gene therapies.
How to plan for uncertainty while maximizing the efficiency of your clinical sup…
The Pharma Data
SEPTEMBER 14, 2020
Supply chain uncertainty is a challenge every clinical supply chain manager wrestles with – stemming from increasing product demand and quality, the growing complexity of clinical trial designs and a lack of visibility in the supply chain. Clinical Trails
How direct-to-patient clinical trial models can accelerate speed-to-market
The Pharma Data
NOVEMBER 26, 2020
Analyzing the benefits and challenges of implementing direct-to-patient services in the clinical supply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market.
Oxford Biomedica and Beam Therapeutics sign CAR-T deal
The Pharma Data
AUGUST 4, 2020
The agreement also puts in place a three year clinical supply agreement for the two companies. Agreement will utilise Oxford Biomedica's LentiVector platform.
AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01
The Pharma Data
DECEMBER 14, 2020
AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. Their lead programme ATX01 is in clinical development in Chemotherapy-Induced Peripheral Neuropathy. 15, 2020 07:15 UTC.
VTX-801 RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR THE TREATMENT OF WILSON DISEASE
The Pharma Data
AUGUST 15, 2021
Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. Pfizer is collaborating with Vivet on the clinical supply of VTX-801 for the Phase 1/2 clinical trial. About GATEWAY – Phase 1/2 Clinical Trial of VTX-801 in Wilson Disease.
Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…
The Pharma Data
SEPTEMBER 18, 2020
The BNT162 program includes five mRNA vaccine candidates currently in clinical testing in the US, Europe, South America and China. has partnered with OmeCare, a CLIA-certified global clinical laboratory provider, to launch a new diagnostic test solution for Covid-19. Clinical Trails
MorphoSys To Present At the 39th Annual J.P. Morgan Healthcare Conference
The Pharma Data
JANUARY 10, 2021
Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development.
PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo Therapeutics Inc. Who Recently Received Orphan Drug Designation from FDA for Esophageal Cancer
The Pharma Data
JANUARY 24, 2021
Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases. Toronto, Ontario–(Newsfile Corp.
Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin(R) Therapeutic Candidate MP0420
The Pharma Data
NOVEMBER 22, 2020
ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / November 23, 2020 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420 (ensovibep), a DARPin® therapeutic candidate for the potential treatment and prevention of COVID-19.
Nordic Nanovector ASA: Results for the Third Quarter 2020
The Pharma Data
NOVEMBER 18, 2020
Lars Nieba, Interim CEO of Nordic Nanovector, said: “Following the successful interim analysis in August and completion of our private placement in September, we are progressing towards the major value inflection point of three-month top-line data from the PARADIGME clinical study, which is targeted for H2 2021. In addition, travel restrictions could create logistical challenges for the shipment of clinical supplies. OSLO, Norway , Nov.
Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19
The Pharma Data
OCTOBER 27, 2020
During the clinical development stage, Molecular Partners will provide clinical supply. The companies will work together to scale-up manufacturing capacity, in collaboration with Sandoz, the generics and biosimilar Novartis division, to provide worldwide supply.
Let's personalize your content